A lipid nanocapsule for oral administration including a solid lipid outer shell and a lipophilic liquid inner core having reverse micelles loaded with one or more incretin mimetics. Also, a method for treating and/or preventing a disorder associated with a GLP-1 dysfunction, the method including a step of administering the therapeutically effective amount of the lipid to a subject in need thereof.
The present invention relates to a binding agent capable of specifically binding to and inhibiting competitively a neutrophil elastase, which binding agent comprises an immunoglobulin single variable domain (ISVD), as well as related products, methods, and uses, such as in particular methods and uses aimed at the prevention, treatment, or diagnostics of inflammatory diseases.
A composition including one or more bacteria selected from the genus Parabacteroides and/or an extract thereof and/or metabolites thereof. Also, the use of this composition in methods of preventing and/or treating reward dysregulation disorders, including mental disorders, neurological disorders, and combinations thereof, by administering this composition to an individual in need thereof.
In an ionizing particle detection module, an ionizing particle traversing an ionization chamber produces a local ionization in an ionizable medium within the ionization chamber. A matrix of detection pads face the ionization chamber so that respective detection pads cover respective zones in the ionization chamber. Respective detection channels comprise respective mutually exclusive groups of detection pads. A detection channel provides an indication of a local ionization occurring somewhere within the respective zones in the ionization chamber covered by the respective detection pads of the detection channel. A cluster of detection pads is identified among the detection pads belonging to detection channels simultaneously providing indications of local ionization. A traversing point indication is provided on the basis of the cluster that has been identified if the cluster comprises a predefined minimum number of detection pads. The traversing point indication indicating where the ionizing particle has traversed the ionization chamber.
An electric machine comprises a rotor from which a magnetic field emanates and a stator that produces a magnetic field that interacts with the magnetic field emanating from the rotor. The stator comprising a pair of windings symmetrically positioned with respect to the rotor. A displacement of the rotor causes an increase in magnitude of a magnetic flux induced by the rotor in one winding of the pair of windings and a decrease in magnitude of a magnetic flux induced by the rotor in the other winding of the pair of windings. A driver can make the electric machine operate in an active electromagnetic bearing mode and in a passive electromagnetic bearing mode. In the active electromagnetic bearing mode, the driver applies a suspension signal component to at least one winding of the pair of windings. This causes the magnetic field produced by the stator to have a component that exerts a suspension force on the rotor through interaction with the magnetic field emanating from the rotor. In the passive electromagnetic bearing mode, the driver interconnects the pair of windings of the stator with each other so that the increase in magnitude of the magnetic flux in the one winding and the decrease in magnitude in the other winding of the pair of windings generates a suspension current in the pair of windings. The suspension current causes the magnetic field produced by the stator to have a component that exerts a restoring force on the rotor counteracting the displacement.
The current invention relates to a population comprising human allogenic liver-derived progenitor cells (HALPC), lysates thereof and/or conditioned medium obtainable by culturing said HALPC, for use in the prevention and/or treatment of a patient at risk of or suffering from hepatocellular carcinoma (HCC). The invention also relates to a pharmaceutical composition for use in the prevention and/or treatment of a patient at risk of or suffering from HCC; to a method for the prevention and/or the treatment of a patient at risk of or suffering from HCC; and to a method for reducing HCC growth rate in a patient suffering from HCC.
Plasmid DNA can be efficiently recovered from bacterial cells when producing plasmid DNA using E. coli. Provided is a method for producing plasmid DNA including the following steps (a) to (c): (a) a step of preparing E. coli, which has a mutation in a gene region associated with maintaining outer membrane properties and has a desired plasmid; (b) a step of culturing E. coli of (a); and (c) a step of recovering a desired plasmid from bacterial cells after culture.
A film (100) is applied as an intermediate between two parts to be joined in a liquid composite molding process, whereby at least one of the two parts comprises a fiber structure. The film (100) has two main surfaces one of which is adapted to contact one of the two parts to be joined, the other main surface being adapted to contact the other one of the two part to be joined. The film (100) comprises a plurality of cavities. An orthographic projection (301-306) of the cavities onto one (101) of the two main surfaces as a projection plane, occupies at least 5 % of this main surface (101).
B29C 65/48 - Joining of preformed partsApparatus therefor using adhesives
B29C 70/48 - Shaping or impregnating by compression for producing articles of definite length, i.e. discrete articles using matched moulds, e.g. for deforming sheet moulding compounds [SMC] or prepregs and impregnating the reinforcements in the closed mould, e.g. resin transfer moulding [RTM]
B29C 70/08 - Fibrous reinforcements only comprising combinations of different forms of fibrous reinforcements incorporated in matrix material, forming one or more layers, with or without non-reinforced layers
B32B 7/12 - Interconnection of layers using interposed adhesives or interposed materials with bonding properties
C09J 7/10 - Adhesives in the form of films or foils without carriers
C09J 11/00 - Features of adhesives not provided for in group , e.g. additives
B29C 70/54 - Component parts, details or accessoriesAuxiliary operations
B33Y 80/00 - Products made by additive manufacturing
C09J 5/06 - Adhesive processes in generalAdhesive processes not provided for elsewhere, e.g. relating to primers involving heating of the applied adhesive
9.
SYSTEM AND METHOD FOR DETERMINING A RISK OF HAVING OR DEVELOPING STEATOHEPATITIS AND/OR A COMPLICATION THEREOF
A computer-implemented method for determining a risk of having or developing steatohepatitis and/or a complication thereof in a subject. The method includes the steps of: receiving at least one image of the subject and at least one clinical and/or biological data, both previously obtained from the subject; calculating a score of fat infiltration heterogeneity on the at least one image based on at least one radiomic feature obtained for a region of interest including at least one skeletal muscle; combining the calculated score of fat infiltration heterogeneity with the at least one clinical and/or biological data previously obtained from the subject; determining a risk for the subject of having or developing steatohepatitis and/or a complication thereof based on the combination of the calculated score of fat infiltration heterogeneity with the at least one clinical and/or biological data.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
In a modulated metasurface antenna, a surface wave transducer generates a surface wave when a radio-frequency excitation signal is applied to the surface wave transducer. The surface wave propagates throughout a surface wave propagation medium from the surface wave transducer to a rim of the surface wave propagation medium. The surface wave propagation medium has an electromagnetic surface impedance distribution that exhibits impedance variations that extend from the surface wave transducer to the rim of the surface wave propagation medium. The electromagnetic surface impedance distribution is non-uniform in azimuth direction on the surface wave propagation medium. The surface wave transducer has a non-uniform azimuthal surface wave power distribution so that, compared to a uniform azimuthal surface wave power distribution, a smaller amount of surface wave power is launched in the azimuth ranges where the impedance variations are the smallest.
H01Q 15/00 - Devices for reflection, refraction, diffraction or polarisation of waves radiated from an antenna, e.g. quasi-optical devices
H01Q 3/26 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the relative phase or relative amplitude of energisation between two or more active radiating elementsArrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the distribution of energy across a radiating aperture
H01Q 13/28 - Non-resonant leaky-waveguide or transmission-line antennas Equivalent structures causing radiation along the transmission path of a guided wave comprising elements constituting electric discontinuities and spaced in direction of wave propagation, e.g. dielectric elements or conductive elements forming artificial dielectric
11.
TITANIUM ALLOY, POWDER OF THE TITANIUM ALLOY AND METHOD OF MANUFACTURING THEREOF
The present invention relates to the field of metallurgy, more particularly non-ferrous alloys. The first aspect of the present invention relates in particular to titanium (Ti) alloys suitable to be manufactured by a method of additive manufacturing such as laser powder bed fusion. The titanium alloy, according to the present invention, comprises titanium and further metallic elements homogenously dispersed in the titanium alloy matrix, wherein titanium forms a microstructural titanium alloy matrix. The alloy microstructure, when the alloy is subjected to mechanical loading, changes its microstructure from an initial non-deformed state to a final deformed state through a martensitic transformation or a mechanical twinning. The alloy comprises a plurality of defects and a plurality of porosities, wherein the plurality of defects and said plurality of porosities represent between 0,5% and 6% in volume of the alloy.
A polypeptide including the amino acid sequence of formula (I): GX1MMX2LQHGSX3X4X5QTP. These polypeptides modulate the activity of the native tetrameric lactate dehydrogenase LDH-1, by inhibiting the tetramerization of its subunits. Also, the therapeutic use of these polypeptides as a medicament, in particular for the prevention and/or the treatment of cancer.
The present invention relates to a method for detecting CALR mutant positive cells in a subject comprising detecting Transferrin Receptor Protein 1 (TFRC) surface levels. The present invention further relates to methods for sorting out CALR mutant cells from health cells, and to methods for treating CALR mutant positive MPNs.
The present invention relates to a population of cells overexpressing the cytochrome c oxidase subunit VIIb (COX7B) protein, for use in treating and/or preventing a brain disease or disorder in a subject in need thereof, and pharmaceutical compositions or kits comprising the same. The present invention further relates to a method for inducing the brain tropism of cells, preferably stem cells, by using the overexpression of COX7B.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Lactam or lactone derivatives of formula Ia:
Lactam or lactone derivatives of formula Ia:
Lactam or lactone derivatives of formula Ia:
or a pharmaceutically acceptable salt or solvate thereof, wherein X1 is NH or O; X2 is —OH, —O-alkyl, —NH2, an amino acid group or a peptide group, wherein the amino acid group or peptide group is linked to the carbonyl group by its N-terminal residue; Z1 is S, SO, SO2, O, CR3 or NR4; and R1, R2, R3 and R4 each independently are H, alkyl or aryl. Also, the use of lactam or lactone derivatives of formula Ia in treating a disease caused by a viral infection, especially a coronavirus infection and/or a viral respiratory infection, such as COVID-19 caused by SARS-CoV-2.
A61K 31/54 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
A continuous process for the production of sodium bicarbonate crystals from the carbon dioxide of a gas stream including an absorption step of the carbon dioxide from a gas stream into an aqueous solution including a sodium carbonate salt to produce an aqueous solution of sodium bicarbonate, then a crystallization step of the sodium bicarbonate salt obtained at the first step. A system for the production of sodium bicarbonate crystals from carbon dioxide of a gas stream including a control unit, an absorption unit and a crystallization unit.
C01D 7/10 - Preparation of bicarbonates from carbonates
C30B 7/04 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent using aqueous solvents
18.
RF SUBSTRATE COMPRISING DEPLETION REGIONS INDUCED BY FIELD EFFECT
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (France)
UNIVERSITE CATHOLIQUE DE LOUVAIN (Belgium)
Inventor
Hutin, Louis
Moulin, Maxime
Fache, Thibaud
Plantier, Christophe
Raskin, Jean-Pierre
Rack, Martin
Abstract
A structure for an RF device provided with a semiconductor region coated with a heterogeneous dielectric region, the heterogeneous dielectric region including, in at least one first direction parallel to a main plane of the substrate, an alternation of first areas made of a first dielectric material with positive fixed charges and of second dielectric areas made of a second dielectric material with negative fixed charge in order to create an alternation of polarity allowing preventing the formation of a parasitic conduction layer in the semiconductor region.
The present invention relates to an optical lens for augmented visual perception of a scene, the optical lens comprising a bandpass filter or a blurring filter, so as to lower contrast and high spatial frequencies of the scene.
G02C 7/10 - Filters, e.g. for facilitating adaptation of the eyes to the darkSunglasses
20.
PARAPHARMACEUTICAL OR PHARMACEUTICAL COMPOSITION ADMINISTRABLE TO A LIVING BEING, PREFERABLY A HUMAN BEING, COMPRISING AT LEAST ONE ENZYME FOR THE TREATMENT AND/OR PREVENTION OF BACTERIAL INFECTIONS INVOLVING BIOFILM FORMATION
A parapharmaceutical or pharmaceutical composition is administrable to living beings, and in particular to human beings. The composition includes at least one endoribonuclease enzyme chosen from the EC 3.1.30 and EC 3.1.31 classes, preferably in a content of from 10 to 1000 U/ml, preferably 50 to 500 U/ml, preferably from 100 to 500 U/ml. The composition is for curative or preventive treatment for dermatological infections or for infections which develop on superficial or deep burns and wounds.
A bacterium belonging to a novel bacterial genus, Dysosmobacter. Also, the therapeutic, nutraceutical and cosmetic use thereof. The uses include methods for treating a disorder, promoting weight loss, decreasing food intake, increasing muscle mass, decreasing fat mass, increasing satiety, and/or decreasing weight gain associated with food intake in a subject, including administering to the subject at least one isolated bacterium belonging to the genus Dysosmobacter and/or a variant thereof and/or fragments thereof.
Genetically modified gram-negative bacteria, in particular E. coli, that are oversensitive to lysis. These bacteria are therefore useful to improve the yield of nucleic acid extraction, preferably extra-genomic nucleic acid extraction (e.g. plasmid), and/or the yield of a polypeptide, preferably encoded by an extra-genomic nucleic acid. In practice, the strains of E. coli are engineered with a combination of at least 2 mutated genes altering the envelop integrity. More particularly, at least one mutated gene is ompA and at least one mutated gene is a gene involved in Lpp functionality, such as, e.g., the lpp gene, the ybiS gene, the ycfS gene and the erfK gene. These combinations also include mutations in genes that are homologue to the ompA gene, and/or the lpp gene.
The present invention relates to a polypeptide comprising fragments of the extracellular domain of thrombopoietin receptor, a fusion protein and a pharmaceutical composition comprising said polypeptide, and uses thereof.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
24.
SOLUBLE THROMBOPOIETIN RECEPTOR FRAGMENTS AND USES THEREOF
The present invention relates to a polypeptide comprising the extracellular domain of the thrombopoietin receptor or fragments thereof, and its use as a medicament. The present invention also relates to the treatment and/or prevention of thrombopoietin-related diseases, in particular myeloproliferative neoplasms.
The present invention relates to a population of human allogenic liver-derived progenitor cells (HALPC), lysates thereof and/or conditioned medium obtainable by culturing said HALPC, for treating and/or preventing cellular senescence in a subject in need thereof. The treatment and/or prevention of cellular senescence using the cell population of the invention, a lysate thereof and/or a conditioned medium obtainable by its culture, has a positive effect on other diseases, in particular diseases associated with cellular senescence.
The present invention relates to a device for heart valve repair configured to be implanted around a heart valve of a subject, the heart valve comprising an annulus and at least two leaflets, the device comprising: a base configured to fit around the annulus of the heart valve, so as to limit a radially outward displacement of said annulus; at least two elongated members extending from the base, each elongated member extending parallel to a longitudinal axis and ending in a free top opposite to the base and being sized to extend between the annulus of the heart valve and a commissure between the at least two leaflets; a securing member configured to join at least two free tops, so as to limit an outward displacement of said free tops when the device is implanted around the heart valve.
The present invention relates to antibodies capable of activating TGF-β1, in particular antibodies that can bind to latent TGF-β1 and release the mature TGF-β1 cytokine, and uses thereof.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
The present invention relates to bispecific antibodies or antibody fragments thereof comprising an antigen binding region that binds to latent TGF-β1 and an antigen binding region that binds to GARP, and uses thereof.
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
29.
METHODS AND COMPOSITIONS FOR INCREASING STRESS TOLERANCE OF CELLS AND ORGANISMS
The present application provides an in vitro method for increasing tolerance of a cell to a stress factor, such as radiation, wherein said method comprises genetically engineering the cell to express a specific DNA ligase or a biologically active fragment thereof. Also genetically engineered cells that express the specific DNA ligase or a biologically active fragment thereof are provided, as well as recombinant polynucleotides comprising a polynucleotide that encodes the specific DNA ligase or a biologically active fragment thereof. Further, the genetically engineered cells are provided for use as a medicament or in a pharmaceutical composition. Finally, also method of using the genetically engineered cells in an environment characterized by radiation that is higher than terrestrial background is provided.
A wake produced by a leader aircraft and experienced by a follower aircraft is sensed by repetitively carrying out the following operations in an iterative manner. Measurements carried out by the follower aircraft are estimated based on a simulated response of the follower aircraft to an estimated aerodynamic context. The estimated aerodynamic context includes a model of the wake and an estimated position of the follower aircraft with respect to the model of the wake and data indicating aerodynamic effects experienced by the follower aircraft due to its own motion. The estimated aerodynamic context is adjusted based on a comparison between the measurements that have been estimated and actual measurements carried out by the follower aircraft, aiming to reduce a deviation between the measurements that have been estimated and the actual measurements. Information on the wake is extracted from the estimated aerodynamic context.
In an energy harvesting system, a power extraction circuit extracts electrical power from an environmental power source susceptible of providing a level of power that fluctuates. An electrical power storage device stores the electrical power extracted from the environmental power source by the power extraction circuit. A sensing circuit provides an indication of a level of power that the power extraction circuit can extract from the environmental power source. A controlled switch circuit electrically decouples the power extraction circuit from the electrical power storage device when the indication indicates that the level of power that the power extraction circuit can extract from the environmental power source is insufficient for the power extraction circuit to charge the electrical power storage device. This prevents leakage of harvested power.
The present invention relates to the treatment of cancer. In particular, the invention relates to the therapeutic use of alpha-2 adrenergic receptor agonists for the treatment of cancer. More particularly, apraclonidine, clonidine, guanfacine and guanabenz, which are alpha-2 adrenergic receptor agonists, are all capable of efficiently reducing the growth of solid tumors. The effect is immune-mediated and is abolished in the presence of an alpha-2 antagonist or in mice that are knockout for the alpha-2 adrenergic receptor.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
34.
ALPHA-2 ADRENERGIC RECEPTOR AGONISTS FOR THE PREVENTION AND/OR THE TREATMENT OF SPLEEN DISORDERS
The present invention relates to the therapeutic use of alpha-2 adrenergic receptor agonists in the prevention and/or treatment of spleen disorders, in particular splenomegaly. The inventors showed that clonidine, guanabenz and romifidine efficiently reduced the spleen weight of animal models with cancer-induced splenomegaly, immunization-induced splenomegaly or splenomegaly induced by myelofibrosis.
In an ionizing particle detection module (100), an ionizing particle traversing an ionization chamber (103) produces a local ionization in an ionizable medium within the ionization chamber (103). A matrix of detection pads (104) face the ionization chamber (103) so that respective detection pads cover respective zones in the ionization chamber (103). Respective detection channels (105) comprise respective mutually exclusive groups of detection pads according to the following rules. Firstly, the detection pads of a detection channel are nonadjacent and dispersed throughout the matrix. Secondly, two detection channels have a maximum of two detection pads next to each other in the matrix, one of the two detection pads belonging to one of the two detection channels, the other of the two detection pads belonging to the other of the two detection channels. A detection channel (107) provides an indication of a local ionization occurring somewhere within the respective zones in the ionization chamber (103) covered by the respective detection pads of the detection channel (107). A cluster of detection pads is identified among the detection pads belonging to detection channels simultaneously providing indications of local ionization. A traversing point indication is provided (102) on the basis of the cluster that has been identified if the cluster comprises a predefined minimum number of detection pads. The traversing point indication indicating where the ionizing particle has traversed the ionization chamber (103).
The present invention relates to a glycocluster comprising at least two acetylated-sialic acids covalently linked to a macrocycle, wherein said macrocycle is selected from porphyrins, pillararenes, calixarenes and fullerenes. According to one embodiment, each acetylated-sialic acid is independently selected from 4-O-acetylated-sialic acid, 7-O-acetylated-sialic acid, 8-O-acetylated-sialic acid and 9-O-acetylated-sialic acid. This invention also relates to a glycocluster for use in the treatment and/or prevention of an infectious disease, such as a coronavirus infection.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07H 1/00 - Processes for the preparation of sugar derivatives
C07H 15/26 - Acyclic or carbocyclic radicals, substituted by hetero rings
C07H 23/00 - Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
The present invention relates to a glycocluster comprising at least two acetylated-sialic acids covalently linked to a macrocycle, wherein said macrocycle is selected from porphyrins, pillararenes, calixarenes and fullerenes. According to one embodiment, each acetylated-sialic acid is independently selected from 4-O-acetylated-sialic acid, 7-O-acetylated-sialic acid, 8-O-acetylated-sialic acid and 9-O-acetylated-sialic acid. This invention also relates to a glycocluster for use in the treatment and/or prevention of an infectious disease, such as a coronavirus infection.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
NATIONAL UNIVERSITY CORPORATION KYUSHU UNIVERSITY (Japan)
UNIVERSITÉ CATHOLIQUE DE LOUVAIN (Belgium)
Inventor
Kin, Tadahiro
Cortina Gil, Eduardo
Giammanco, Andrea
Abstract
Providing a magnetic field structure imaging apparatus capable of easily obtaining a magnetic field structure image of a target region. A magnetic field structure imaging apparatus comprising: a first detection unit that detects a passing position of a muon having passed through a target region; a second detection unit that detects a passing position of the muon having passed through the target region and the first detection unit; an analysis unit that calculates a magnetic field structure image of the target region on the basis of an arrival trajectory of the muon detected by the first detection unit and the second detection unit; and a display unit that displays at least one of the magnetic field structure image and magnitude and/or direction of two-dimensional magnetic flux density calculated from the magnetic field structure image, wherein a cosmic ray muon is used as the muon; and magnetic field structure imaging method.
G01N 23/04 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by transmitting the radiation through the material and forming images of the material
39.
PREVENTION AND/OR TREATMENT OF REWARD DYSREGULATION DISORDERS
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention relates to a composition comprising one or more bacteria from the genus Parabacteroides and/or an extract thereof, for use in preventing and/or treating reward dysregulation disorders.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
41.
PREVENTION AND/OR TREATMENT OF REWARD DYSREGULATION DISORDERS
The present invention relates to a composition comprising one or more bacteria from the genus Parabacteroides and/or an extract thereof, for use in preventing and/or treating reward dysregulation disorders.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The purpose of the present invention is to collect plasmid DNA from a cell body of Escherichia coli with high efficiency in the production of the plasmid DNA using the Escherichia coli. Provided is a method for producing plasmid DNA, the method comprising the following steps (a) to (c): (a) preparing Escherichia coli that has a mutation in a gene region involved in the retention of the properties of an outer membrane thereof and carries a desired plasmid; (b) culturing the Escherichia coli prepared in the step (a); and (c) collecting the desired plasmid from the cultured cells.
An electric machine (300) comprises a rotor (303) from which a magnetic field emanates and a stator that produces a magnetic field that interacts with the magnetic field emanating from the rotor. The stator comprising a pair of windings (304, 305) symmetrically positioned with respect to the rotor (303). A displacement of the rotor (303) causes an increase in magnitude of a magnetic flux induced by the rotor (303) in one winding of the pair of windings (304, 305) and a decrease in magnitude of a magnetic flux induced by the rotor (303) in the other winding of the pair of windings (304, 305). A driver (301) can make the electric machine operate in an active electromagnetic bearing mode and in a passive electromagnetic bearing mode. In the active electromagnetic bearing mode, the driver (301) applies a suspension signal component to at least one winding of the pair of windings. This causes the magnetic field produced by the stator to have a component that exerts a suspension force on the rotor (303) through interaction with the magnetic field emanating from the rotor (303). In the passive electromagnetic bearing mode, the driver (301) interconnects the pair of windings (304, 305) of the stator with each other so that the increase in magnitude of the magnetic flux in the one winding and the decrease in magnitude in the other winding of the pair of windings (304, 305) generates a suspension current in the pair of windings (304, 305). The suspension current causes the magnetic field produced by the stator to have a component that exerts a restoring force on the rotor (303) counteracting the displacement.
The present invention relates to a computer-implemented method for determining a risk of having or developing steatohepatitis and/or a complication thereof in a subject, said method comprising the steps of: receiving (11) at least one image of the subject (20) and at least one clinical and/or biological data (21), both previously obtained from the subject; calculating a score of fat infiltration heterogeneity on the at least one image (12) based on at least one radiomic feature obtained for a region of interest (ROI) comprising at least one skeletal muscle; combining the calculated score of fat infiltration heterogeneity with the at least one clinical and/or biological data previously obtained from the subject (13); determining (14) a risk (30) for the subject of having or developing steatohepatitis and/or a complication thereof based on the combination of the calculated score of fat infiltration heterogeneity with the at least one clinical and/or biological data (21).
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
45.
SYSTEM AND METHOD FOR DETERMINING A RISK OF HAVING OR DEVELOPING STEATOHEPATITIS AND/OR A COMPLICATION THEREOF
The present invention relates to a computer-implemented method for determining a risk of having or developing steatohepatitis and/or a complication thereof in a subject, said method comprising the steps of: receiving (11) at least one image of the subject (20) and at least one clinical and/or biological data (21), both previously obtained from the subject; calculating a score of fat infiltration heterogeneity on the at least one image (12) based on at least one radiomic feature obtained for a region of interest (ROI) comprising at least one skeletal muscle; combining the calculated score of fat infiltration heterogeneity with the at least one clinical and/or biological data previously obtained from the subject (13); determining (14) a risk (30) for the subject of having or developing steatohepatitis and/or a complication thereof based on the combination of the calculated score of fat infiltration heterogeneity with the at least one clinical and/or biological data (21).
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
A device (100) having a proximal end (20) and end a distal end (40) for withdrawal of a liquid sample, fractionation, and separation of one or more fractions comprising: a piston assembly (300) comprising a piston (302) dismountably attached at its proximal end (20) to an actuating rod (350); a container (200) having a body (202) disposed with a cylindrical chamber (204) for slidable movement of the piston (302) therein; wherein the cylindrical chamber (204) is provided at the distal end (40) with a resealable septum (410) for co-operation with a puncture needle assembly (600) for withdrawal of the liquid sample, an at the proximal end (20) with a stop member (206), which stop member (206) limits movement of the piston (300) in a proximal direction, wherein the container body (202) is dimensioned to fit inside a centrifuge rotor, and is configured for breakability into two parts at a temperature of 0 deg C. or lower at a breakable zone (210).
The present invention relates to the use of the expression levels of at least three biomarkers selected from the group consisting of SLC7A11, SERPINE1, PSAT1, PHGDH-1, TXNRD1, VIM, SNAI1, ZEB1, NANOG, SOX2, PCK2, G6PD, ASNS, NUPR1 and SLC6A9 as a molecular signature for identifying an individual with cancer, in particular breast cancer, as being susceptible to respond to a treatment by a mitochondria-targeted antioxidant.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
48.
MOLECULAR SIGNATURE FOR ASSESSING THE RESPONSIVENESS OF CANCER TO MITOCHONDRIA-TARGETED ANTIOXIDANTS
The present invention relates to the use of the expression levels of at least three biomarkers selected from the group consisting of SLC7A11, SERPINE1, PSAT1, PHGDH-1, TXNRD1, VIM, SNAI1, ZEB1, NANOG, SOX2, PCK2, G6PD, ASNS, NUPR1 and SLC6A9 as a molecular signature for identifying an individual with cancer, in particular breast cancer, as being susceptible to respond to a treatment by a mitochondria-targeted antioxidant.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
In a modulated metasurface antenna, a surface wave transducer generates a surface wave when a radio-frequency excitation signal is applied to the surface wave transducer. The surface wave propagates throughout a surface wave propagation medium from the surface wave transducer to a rim of the surface wave propagation medium. The surface wave propagation medium has an electromagnetic surface impedance distribution (1000) that exhibits impedance variations that extend from the surface wave transducer to the rim of the surface wave propagation medium. The electromagnetic surface impedance distribution is non-uniform in azimuth direction on the surface wave propagation medium. Accordingly, there are azimuth ranges in which the impedance variations are smallest from the surface wave transducer to the rim of the surface wave propagation medium. The surface wave transducer has a non-uniform azimuthal surface wave power distribution so that, compared to a uniform azimuthal surface wave power distribution, a smaller amount of surface wave power is launched in the azimuth ranges (1001, 1002) where the impedance variations are the smallest. Accordingly, a significant proportion of the surface wave may leak from the surface wave propagation medium to produce radiation. This may significantly increase efficiency of the modulated metasurface antenna compared with prior art techniques.
H01Q 3/26 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the relative phase or relative amplitude of energisation between two or more active radiating elementsArrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the distribution of energy across a radiating aperture
H01Q 13/28 - Non-resonant leaky-waveguide or transmission-line antennas Equivalent structures causing radiation along the transmission path of a guided wave comprising elements constituting electric discontinuities and spaced in direction of wave propagation, e.g. dielectric elements or conductive elements forming artificial dielectric
H01Q 15/00 - Devices for reflection, refraction, diffraction or polarisation of waves radiated from an antenna, e.g. quasi-optical devices
A lipid nanocapsule for oral administration including a solid lipid outer shell and a lipophilic liquid inner core having reverse micelles loaded with one or more incretin mimetics. Also, a method for treating and/or preventing a disorder associated with a GLP-1 dysfunction, the method including a step of administering the therapeutically effective amount of the lipid to a subject in need thereof.
A vaccine for treating and/or preventing a brain tumor. More particularly, a modified vesicular stomatitis virus glycoprotein (VSV-G) including at least one tumor antigen, or a fragment thereof, for use in preventing and/or treating a brain tumor in an individual in need thereof, when administered before a surgery intended to remove all or part of the tumor, such as, a tumor resection. The inventors have shown that vaccination of individual with a brain tumor with a vaccine including a nucleic acid sequence encoding a modified VSV-G may be combined to a tumor resection in order to ameliorate the prognostic of the individuals.
A radiofrequency transducer assembly includes an antenna structure of the birdcage type. This antenna structure has longitudinally extending segments, which are arranged in a cylindrical configuration around a center axis, and at least one transversally oriented circular electrical coupling between the longitudinally extending segments. An electrically conductive shield surrounds the antenna structure of the birdcage type. The radiofrequency transducer assembly comprises a pair of electrically conductive bridges between a longitudinally extending segment of the antenna structure and the electrically conductive shield, which thereby jointly form an inductive loop.
The present invention relates to a method for manufacturing multi-pixel gas microsensors, wherein each multi-pixel gas microsensor comprises at least a first pixel group having a first sensing material and a second pixel group having a second sensing material different from the first material. The method comprises a first step of providing a wafer substrate and processing the wafer substrate for building a plurality of multi-pixel microsensors having first and second groups of pixels, a second step of selecting sensing materials for each of the groups of pixels, and a third step of activation of the first and the second pixel group by coating electrode pairs of the first and second pixel group with the corresponding sensing materials selected.
A polypeptide that modulates the activity of at least one isoform of the native tetrameric lactate dehydrogenase, and the use thereof as a medicament for the treatment of a cancer. More particularly, linear and cyclic polypeptides that inhibit the tetramerization of the lactate dehydrogenase subunits, and compositions and kits including the polypeptides.
Provided is an instrument (100) for gauging a free margin (420) length (FML) of a heart valve cusp (410) in a vessel (416) comprising a gauging head (200) having a proximal (20) and distal end (40) comprising a body (210) having a prising member (212) at the distal (40) end adapted to be received within a cusp pocket (428) of the heart valve cusp and which extends in a proximal (20) direction to form a gauging member (220) of a fixed and defined length (L) adapted to abut the free margin (420), wherein the gauging member (220) comprises at either end a contact probe (222-a, 222-b) spaced apart by the fixed and defined length (L) and adapted to abut a vessel wall where the free margin edges attach.
The present invention relates to a polypeptide comprising the amino acid sequence of formula (I): GX1MMX2LQHGSX3X4X5QTP. These polypeptides modulate the activity the native tetrameric lactate dehydrogenase LDH-1, by inhibiting the tetramerization of its subunits. The invention also relates to the therapeutic use of these polypeptides as a medicament, in particular for the prevention and/or the treatment of cancer.
The present invention relates to a polypeptide comprising the amino acid sequence of formula (I): GX1MMX2LQHGSX3X4X5QTP. These polypeptides modulate the activity the native tetrameric lactate dehydrogenase LDH-1, by inhibiting the tetramerization of its subunits. The invention also relates to the therapeutic use of these polypeptides as a medicament, in particular for the prevention and/or the treatment of cancer.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
YNCREA HAUTS DE FRANCE (France)
UNIVERSITE POLYTECHNIQUE DES HAUTS DE FRANCE (France)
UNIVERSITE CATHOLIQUE DE LOUVAIN (Belgium)
Inventor
Szunerits, Sabine
Boukherroub, Rabah
Melinte, Sorin
Abstract
The present invention relates to a cutaneous device (2) for the storage and release of molecules, in particular therapeutic molecules, comprising: —a support (6), —a matrix (8) configured to store and release the molecules as a function of the temperature, and —an electro-resistive layer, disposed between the support and the matrix, intended to be subjected to a voltage and comprising at least one thin microporous and/or nanoporous metal layer. The present invention also relates to a transcutaneous delivery device and the corresponding methods of manufacture and use.
The present invention relates to a continuous process for the production of sodium bicarbonate crystals from the carbon dioxide of a gas stream comprising an absorption step of the carbon dioxide from a gas stream into an aqueous solution comprising a sodium carbonate salt to produce an aqueous solution of sodium bicarbonate, then a crystallization step of the sodium bicarbonate salt obtained at the first step. The invention also relates to a system for the production of sodium bicarbonate crystals from carbon dioxide of a gas stream comprising a control unit 10, an absorption unit 20 and a crystallization unit 30.
The present invention relates to a continuous process for the production of sodium bicarbonate crystals from the carbon dioxide of a gas stream comprising an absorption step of the carbon dioxide from a gas stream into an aqueous solution comprising a sodium carbonate salt to produce an aqueous solution of sodium bicarbonate, then a crystallization step of the sodium bicarbonate salt obtained at the first step. The invention also relates to a system for the production of sodium bicarbonate crystals from carbon dioxide of a gas stream comprising a control unit 10, an absorption unit 20 and a crystallization unit 30.
C01D 7/10 - Preparation of bicarbonates from carbonates
B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
B01D 63/00 - Apparatus in general for separation processes using semi-permeable membranes
61.
LACTAM AND LACTONE DERIVATIVES OF FORMULA (IA) FOR USE IN THE TREATMENT OF DISEASES CAUSED BY A CORONAVIRUS INFECTION AND/OR A VIRAL RESPIRATORY INFECTION
The present invention relates to lactam or lactone derivatives of formula la: or a pharmaceutically acceptable salt or solvate thereof, wherein X1is NH or O; X222, an amino acid group or a peptide group, wherein the amino acid group or peptide group is linked to the carbonyl group by its N-terminal residue; Z122, O, CR3or NR4; and R1, R2, R3and R4 each independently are H, alkyl or aryl;; and their use in treating a disease caused by a viral infection, especially a coronavirus infection and/or a viral respiratory infection, such as COVID-19 caused by SARS-CoV- 2.
A61K 31/45 - Non-condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/54 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
62.
METHOD FOR PRODUCING A COMPOSITION COMPRISING A 3-O-p-COUMAROYL ESTER OF TORMENTIC ACID FROM A PLANT CELL CULTURE, APPLICATIONS THEREOF AS ANTIPARASITIC AGENT FOR THE TREATMENT OF TRYPANOSOMIASIS
LUXEMBOURG INSTITUTE OF SCIENCE AND TECHNOLOGY (Luxembourg)
Université catholique de Louvain (Belgium)
Inventor
Andre, Christelle
Leclercq, Joelle
Beaufay, Claire
Catteau, Lucy
Legay, Sylvain
Abstract
The present invention relates to a method for the production of a (poly)hydroxylated pentacyclic triterpene composition including a 3-O-p-coumaroyl ester of tormentic acid from a plant suspension cell culture, to a pharmaceutical composition comprising at least 3-O-p-coumaroyl ester of tormentic acid for a use in the prevention and/or the treatment of trypanosomiasis, optionally in admixture with other (poly)hydroxylated pentacyclic triterpenes, and to 3-O-p-coumaroyl ester of tormentic acid for its use as an antiparasitic agent for the prevention and/or the treatment of trypanosomiasis, optionally in admixture with other (poly)hydroxylated pentacyclic triterpenes.
A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
C12P 15/00 - Preparation of compounds containing at least three condensed carbocyclic rings
63.
PARAPHARMACEUTICAL OR PHARMACEUTICAL COMPOSITION ADMINISTRABLE TO A LIVING BEING, PREFERABLY A HUMAN BEING, COMPRISING AT LEAST ONE ENZYME FOR THE TREATMENT AND/OR PREVENTION OF BACTERIAL INFECTIONS INVOLVING BIOFILM FORMATION
A parapharmaceutical or pharmaceutical composition administrable to living beings, in particular to human beings, comprising at least one endoribonuclease enzyme chosen from the EC 3.1.30 and EC 3.1.31 classes, preferably in a content of from 10 to 1000 U/ml, preferably 50 to 500 U/ml, preferably from 100 to 500 U/ml, for use in a curative or preventive treatment for dermatological infections or for infections which develop on superficial or deep burns and wounds.
The present invention relates to a method for assessing, evaluating and/monitoring the purity of a mesenchymal stem cells preparation, in particular of an adipose stem cells preparation, comprising measuring the expression level of at least one growth factor.
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
A wake produced by a leader aircraft and experienced by a follower aircraft is sensed by repetitively carrying out the following two operations in an iterative manner. Measurements carried out by the follower aircraft are estimated (311) based on a simulated response of the follower aircraft to an estimated aerodynamic context (309). The estimated aerodynamic context (309) includes, on the one hand, a model of the wake and an estimated position of the follower aircraft with respect to the model of the wake and, on the other hand, data indicating aerodynamic effects experienced by the follower aircraft due to its own motion. The estimated aerodynamic context (309) is adjusted (308) based on a comparison between the measurements that have been estimated (311) and actual measurements (312) carried out by the follower aircraft, aiming to reduce a deviation between the measurements that have been estimated and the actual measurements. Information (313) on the wake is extracted from the estimated aerodynamic context (309).
B64D 45/00 - Aircraft indicators or protectors not otherwise provided for
G01C 23/00 - Combined instruments indicating more than one navigational value, e.g. for aircraftCombined measuring devices for measuring two or more variables of movement, e.g. distance, speed or acceleration
G05D 1/10 - Simultaneous control of position or course in three dimensions
A wake produced by a leader aircraft and experienced by a follower aircraft is sensed by repetitively carrying out the following two operations in an iterative manner. Measurements carried out by the follower aircraft are estimated (311) based on a simulated response of the follower aircraft to an estimated aerodynamic context (309). The estimated aerodynamic context (309) includes, on the one hand, a model of the wake and an estimated position of the follower aircraft with respect to the model of the wake and, on the other hand, data indicating aerodynamic effects experienced by the follower aircraft due to its own motion. The estimated aerodynamic context (309) is adjusted (308) based on a comparison between the measurements that have been estimated (311) and actual measurements (312) carried out by the follower aircraft, aiming to reduce a deviation between the measurements that have been estimated and the actual measurements. Information (313) on the wake is extracted from the estimated aerodynamic context (309).
G05D 1/10 - Simultaneous control of position or course in three dimensions
G01C 23/00 - Combined instruments indicating more than one navigational value, e.g. for aircraftCombined measuring devices for measuring two or more variables of movement, e.g. distance, speed or acceleration
A strain sensor (100) is based on a self-biasing reference circuit that reaches an operating state that, at least at first order, is at least supply-voltage independent. The strain sensor (100) provides an output signal (201, 202) that is defined by the operating state of the self-biasing reference circuit. At least one component (107, 108) in the self-biasing reference circuit has an electrical characteristic that depends on a strain to which the at least one component (107, 108) is subjected. This makes that the operating state of the self-biasing reference circuit depends on the strain. As a result, the output signal (201, 202) of the strain sensor varies as a function of the strain to which the at least one component (107, 108) is subjected.
G01L 1/22 - Measuring force or stress, in general by measuring variations in ohmic resistance of solid materials or of electrically-conductive fluidsMeasuring force or stress, in general by making use of electrokinetic cells, i.e. liquid-containing cells wherein an electrical potential is produced or varied upon the application of stress using resistance strain gauges
G01D 5/16 - Mechanical means for transferring the output of a sensing memberMeans for converting the output of a sensing member to another variable where the form or nature of the sensing member does not constrain the means for convertingTransducers not specially adapted for a specific variable using electric or magnetic means influencing the magnitude of a current or voltage by varying resistance
G01D 3/036 - Measuring arrangements with provision for the special purposes referred to in the subgroups of this group mitigating undesired influences, e.g. temperature, pressure on measuring arrangements themselves
H03F 1/30 - Modifications of amplifiers to reduce influence of variations of temperature or supply voltage
G01B 7/16 - Measuring arrangements characterised by the use of electric or magnetic techniques for measuring the deformation in a solid, e.g. by resistance strain gauge
G01D 3/02 - Measuring arrangements with provision for the special purposes referred to in the subgroups of this group with provision for altering or correcting the transfer function
H03F 3/347 - DC amplifiers in which all stages are DC-coupled with semiconductor devices only in integrated circuits
The present invention relates to an isolated transgenic pig beta cell wherein the PKC and the PKA pathway are constitutively activated; to a transgenic pig islet comprising said transgenic pig beta cell; and to a transgenic pig comprising said transgenic pig beta cell or said transgenic pig islet. Another object of the invention is a device comprising a transgenic pig beta cell or a transgenic pig islet of the invention. The present invention also relates to the use of said transgenic pig beta cell, said transgenic pig islet, or said device for treating a disease, disorder or condition related to the impaired function of endocrine pancreas or of beta cell.
The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.
In an energy harvesting system (400), a power extraction circuit (404) extracts electrical power from an environmental power source susceptible of providing a level of power that fluctuates. An electrical power storage device (406) stores the electrical power extracted from the environmental power source by the power extraction circuit (404). A sensing circuit (407) provides an indication (409) of a level of power that the power extraction circuit (404) can extract from the environmental power source. A controlled switch circuit (408) electrically decouples the power extraction circuit (404) from the electrical power storage device (406) when the indication (409) indicates that the level of power that the power extraction circuit (404) can extract from the environmental power source is insufficient for the power extraction circuit (404) to charge the electrical power storage device (406). This prevents leakage of harvested power.
Guanabenz for use with an immunotherapy in the treatment of a cancer or of an infectious disease. In particular, guanabenz is used as an adjuvant for an immunotherapy, such as a cancer immunotherapy or a vaccination. More specifically, guanabenz for use with an adoptive cell therapy, with a therapeutic vaccine, with a checkpoint inhibitor therapy or with a T-cell agonist therapy in the treatment of a cancer. Also, guanabenz for use with a vaccination in the prophylactic and/or therapeutic treatment of an infectious disease.
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
73.
ALPHA-2 ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER
The present invention relates to the treatment of cancer. In particular, the invention relates to the therapeutic use of alpha-2 adrenergic receptor agonists for the treatment of cancer. More particularly, apraclonidine, clonidine, guanfacine and guanabenz, which are alpha- 2 adrenergic receptor agonists, are all capable of efficiently reducing the growth of solid tumors. The effect is immune-mediated and is abolished in the presence of an alpha-2 antagonist or in mice that are knockout for the alpha-2 adrenergic receptor.
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 31/54 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to the therapeutic use of alpha-2 adrenergic receptor agonists in the prevention and/or treatment of spleen disorders, in particular splenomegaly. The inventors showed that clonidine, guanabenz and romifidine efficiently reduced the spleen weight of animal models with cancer-induced splenomegaly, immunization-induced splenomegaly or splenomegaly induced by myelofibrosis.
The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.
A prosthesis or orthosis for a joint, such as an ankle, which includes a first body, a second body, and an articulated joint between the first and second bodies, the articulated joint allowing the rotation of the first and second bodies with respect to one another around a joint rotation axis. It further includes a locking mechanism configured to selectively lock the rotation between the first and second bodies in one direction, when it is in a locked configuration, and a transmission mechanism such that a rotation of the joint rotation axis generates a movement of a lockable part of the locking mechanism. The axis of the movement of the lockable part is shifted relative to the joint rotation axis and the transmission mechanism includes a reducer configured to reduce effort to lock the rotation of the first body with respect to the second body.
A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces
A61F 2/50 - Prostheses not implantable in the body
An example device includes a processor configured to receive a plurality of voltage values representing respective voltage magnitudes at voltage nodes in a first portion of a power system and determine, for each voltage node, a respective value of first and second voltage-constraint coefficients. The processor is also configured to receive a power value corresponding to a connection point of the first portion of the power system with a second portion of the power system and determine for the connection point, a respective value of first and second power-constraint coefficients. The processor is also configured to cause at least one energy resource connected to the first portion of the power system to modify an output power of the at least one energy resource based on the value of the first and second voltage-constraint coefficients for each voltage node and the value of the first and second power-constraint coefficients.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventor
Batoko, Henri
Moreau, Patrick
Abstract
The present invention relates generally to the field of plant molecular biology and relates to plants having a modified lipid metabolism and to methods for making such modified plants. In particular, the invention provides modified plants and parts thereof, including seeds, having an increased level of triacylglycerol (TAG), by means of a seed-specific expression in seed tissues during seed filling of a nucleic acid encoding a translocator protein (TSPO) in said modified plants or parts thereof. The invention further relates to methods for modulating lipid metabolism in plants and for producing plants with a modified lipid metabolism. The invention also provides constructs, vectors and host cells useful in the methods of the invention, and further relates to products obtained from the modified plants.
A device (100) having a proximal end (20) and end a distal end (40) for withdrawal of a liquid sample, fractionation, and separation of one or more fractions comprising: a piston assembly (300) comprising a piston (302) dismountably attached at its proximal end (20) to an actuating rod (350); a container (200) having a body (202) disposed with a cylindrical chamber (204) for slidable movement of the piston (302) therein; wherein the cylindrical chamber (204) is provided at the distal end (40) with a resealable septum (410) for co-operation with a puncture needle assembly (600) for withdrawal of the liquid sample, an at the proximal end (20) with a stop member (206), which stop member (206) limits movement of the piston (300) in a proximal direction, wherein the container body (202) is dimensioned to fit inside a centrifuge rotor, and is configured for breakability into two parts at a temperature of 0 deg C or lower at a breakable zone (210).
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes DetailsAccessories therefor
A61B 5/154 - Devices for taking samples of blood specially adapted for taking samples of venous or arterial blood, e.g. by syringes using pre-evacuated means
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
81.
Integrated circuit device and method of manufacturing thereof
An integrated circuit device includes a semiconductor substrate having a resistivity of at least 100 Ω·cm. An electrically insulating layer contacts the semiconductor substrate. The electrically insulating layer is susceptible of inducing in the semiconductor substrate a parasitic surface conduction layer that interfaces with the electrically insulating layer. An electrical circuit is located on the electrically insulating layer. The electrical circuit includes a section capable of inducing an electrical field in the semiconductor substrate. The integrated circuit device includes a depletion-inducing junction of which at least a portion is comprised in the semiconductor substrate. The depletion-inducing junction can autonomously induce in the semiconductor substrate a depleted zone that interfaces with a section of the electrically insulating layer that lies in-between two sections of the electrical circuit.
H01L 21/84 - Manufacture or treatment of devices consisting of a plurality of solid state components or integrated circuits formed in, or on, a common substrate with subsequent division of the substrate into plural individual devices to produce devices, e.g. integrated circuits, each consisting of a plurality of components the substrate being other than a semiconductor body, e.g. being an insulating body
H01L 27/12 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including integrated passive circuit elements with at least one potential-jump barrier or surface barrier the substrate being other than a semiconductor body, e.g. an insulating body
A radiofrequency transducer assembly (104) comprises an antenna structure of the birdcage type. This antenna structure has longitudinally extending segments (201), which are arranged in a cylindrical configuration around a center axis, and at least one transversally oriented circular electrical coupling (205) between the longitudinally extending segments. An electrically conductive shield (107) surrounds the antenna structure of the birdcage type. The radiofrequency transducer assembly (104) comprises a pair of electrically conductive bridges (307, 308) between a longitudinally extending segment (201) of the antenna structure and the electrically conductive shield (107), which thereby jointly form an inductive loop (302).
The present invention relates to processes for producing, isolating and recovering various useful components from solid lignocellulosic biomass. More in particular, the invention provides a process for producing lignin components comprising lignin monomers, lignin dimers and lignin oligomers, from lignocellulosic biomass, wherein said lignocellulosic biomass comprises cellulose, hemicellulose and lignin, said process comprising the steps of: a) providing said lignocellulosic biomass as a solid biomass, b) contacting said lignocellulosic biomass with a composition comprising a sulphur containing reducing agent, and an organic solvent, optionally provided in a mixture with water, and obtaining lignin components comprising lignin monomers, lignin dimers and lignin oligomers, and c) isolating and recovering said lignin components. The lignocellulosic biomass provided in step a) is not chemically treated prior to contacting with said composition in step b) but is applied as raw biomass. The present invention also relates to components produced from the lignocellulosic biomass in accordance with disclosed processes and to uses thereof in various applications.
The present invention relates to a vaccine for treating and/or preventing a brain tumor. More particularly, the invention relates to a modified vesicular stomatitis virus glycoprotein (VSV-G) comprising at least one tumor antigen, or a fragment thereof, for use in preventing and/or treating a brain tumor in an individual in need thereof, when administered before a surgery intended to remove all or part of the tumor, such as, a tumor resection. The inventors have shown that vaccination of individual with a brain tumor with a vaccine comprising a nucleic acid sequence encoding a modified VSV-G according to the invention may be combined to a tumor resection in order to ameliorate the prognostic of said individuals.
The present invention relates to a method for manufacturing multi-pixel gas microsensors, wherein each multi-pixel gas microsensor comprises at least a first pixel group having a first sensing material and a second pixel group having a second sensing material different from the first material. The method comprises a first step of providing a wafer substrate and processing the wafer substrate for building a plurality of multi-pixel microsensors having first and second groups of pixels, a second step of selecting sensing materials for each of the groups of pixels, and a third step of activation of the first and the second pixel group by coating electrode pairs of the first and second pixel group with the corresponding sensing materials selected.
The present invention relates to a method for manufacturing multi-pixel gas microsensors, wherein each multi-pixel gas microsensor comprises at least a first pixel group having a first sensing material and a second pixel group having a second sensing material different from the first material. The method comprises a first step of providing a wafer substrate and processing the wafer substrate for building a plurality of multi-pixel microsensors having first and second groups of pixels, a second step of selecting sensing materials for each of the groups of pixels, and a third step of activation of the first and the second pixel group by coating electrode pairs of the first and second pixel group with the corresponding sensing materials selected.
G01N 27/12 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon absorption of a fluidInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon reaction with a fluid
G01N 27/414 - Ion-sensitive or chemical field-effect transistors, i.e. ISFETS or CHEMFETS
87.
Conditioned medium from human adult liver stem cells and its use in the treatment of liver disorders
The invention relates to cell-free compositions obtained by culturing adult-derived human liver stem/progenitor cells (ADHLSC) in cell culture medium and isolating the resulting conditioned medium (ADHLSC-CM) that has advantageous properties, such as anti-fibrotic effects. ADHLSC-CM, compositions based on ADHLSC-CM, and other related and derived products, can be used in cell culture processes or as a medicament, more particularly for the treatment of diseases involving organ injury, organ failure, in organ or cell transplantation or the pathological disruption, inflammation, degeneration, and/or proliferation of cells within a tissue or an organ, in particular within liver.
The present invention relates to pasteurized Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising pasteurized Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of pasteurized Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.
A61K 9/00 - Medicinal preparations characterised by special physical form
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
A61Q 19/06 - Preparations for care of the skin for countering cellulitis
A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
A substrate has a front side including an electrical circuit and a rear side including an exposed zone that faces the electrical circuit. In an electrochemical treatment step, an electrical potential is laterally applied at least to the exposed zone of the rear side of the substrate, while the exposed zone is in contact with a chemically reactive substance. The electrical potential causes a lateral flow of electrical current at least in the exposed zone of the substrate. The lateral flow of current and the chemically reactive substance alter the substrate in at least the exposed zone.
The present invention relates to a lipid nanocapsule for oral administration comprising a solid lipid outer shell and a lipophilic liquid inner core comprising reverse micelles loaded with one or more incretin mimetics. The present invention also relates to the use of lipid nanocapsules for treating and/or preventing a disorder associated with a GLP-1 dysfunction.
p, the turns of the first subgroup being connected in such a way that a current may flow in same direction in all turns of said subgroup, the turns of the second subgroup being connected in such a way that a current may flow in same direction in all turns of said subgroup, a turn of the first subgroup being connected to a turn of the second subgroup in such a way that the direction of said current in the first group is opposite to the direction of the current in the second subgroup. The winding is a wave winding comprising vertical shortcut connections.
The present invention relates to a polypeptide that modulates the activity of at least one isoform of the native tetrameric lactate dehydrogenase, and the use thereof as a medicament for the treatment of a cancer. More particularly, the invention relates to linear and cyclic polypeptides that inhibit the tetramerization of the lactate dehydrogenase subunits.
The present invention relates to a polypeptide that modulates the activity of at least one isoform of the native tetrameric lactate dehydrogenase, and the use thereof as a medicament for the treatment of a cancer. More particularly, the invention relates to linear and cyclic polypeptides that inhibit the tetramerization of the lactate dehydrogenase subunits.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
YNCREA HAUTS DE FRANCE (France)
UNIVERSITE POLYTECHNIQUE DES HAUTS DE FRANCE (France)
UNIVERSITE CATHOLIQUE DE LOUVAIN (Belgium)
Inventor
Szunerits, Sabine
Boukherroub, Rabab
Melinte, Sorin
Abstract
The present invention relates to a cutaneous device (2) for the storage and release of molecules, in particular therapeutic molecules, comprising: - a support (6), - a matrix (8) configured to store and release the molecules as a function of the temperature, and - an electro-resistive layer, disposed between the support and the matrix, intended to be subjected to a voltage and comprising at least one thin microporous and / or nanoporous metal layer. The present invention also relates to a transcutaneous delivery device and the corresponding methods of manufacture and use.
p, the turns of the first subgroup being connected in such a way that a current may flow in same direction in all turns of said subgroup, the turns of the second subgroup being connected in such a way that a current may flow in same direction in all turns of said subgroup, a turn of the first subgroup being connected to a turn of the second subgroup in such a way that the direction of said current in the first group is opposite to the direction of the current in the second subgroup.
LUXEMBOURG INSTITUTE OF SCIENCE AND TECHNOLOGY (LIST) (Luxembourg)
UNIVERSITÉ CATHOLIQUE DE LOUVAIN (Belgium)
Inventor
Leclercq, Joëlle
Beaufay, Claire
Catteau, Lucy
Andre, Christelle
Legay, Sylvain
Abstract
O-pO-pO-pO-p-coumaroyl ester of tormentic acid for its use as an antiparasitic agent for the prevention and/or the treatment of trypanosomiasis, optionally in admixture with other (poly)hydroxylated pentacyclic triterpenes.
Aspects of the invention concern a composition or a kit-of-parts comprising i) a virus which is a member of the Reoviridae family and ii) sialic acid and/or a molecule comprising at least one sialic acid moiety, as well therapeutic applications thereof.
A61K 31/7012 - Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
Aspects of the invention concern a composition or a kit-of-parts comprising i) a virus which is a member of the Reoviridae family and ii) sialic acid and/or a molecule comprising at least one sialic acid moiety, as well therapeutic applications thereof.
A61K 31/7012 - Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
